Cagrilintide and Survodutide are both Metabolic peptides, but they're studied for different things. In short, Cagrilintide is a long-acting amylin analog studied for appetite and weight, often with semaglutide, while Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight and liver health. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
Cagrilintide vs Survodutide at a glance
| Cagrilintide | Survodutide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | A long-acting amylin analog studied for appetite and weight, often with semaglutide. | An investigational GLP-1/glucagon dual agonist studied for weight and liver health. |
| Researched for | Appetite regulation, Weight management, Satiety | Weight management, Liver health (MASH), Metabolic health |
| Research status | Clinical trials — investigational. | Clinical trials — investigational. |
| Typically stacked with | Semaglutide | — |
| Key consideration | Investigational and not approved as a standalone product. Medical supervision advised. | Not approved. Investigational compound; use only under medical supervision. |
How does Cagrilintide work?
Cagrilintide is a long-acting analog of amylin, a hormone co-released with insulin that promotes satiety and slows gastric emptying. It is studied on its own and combined with semaglutide (as CagriSema) for appetite and weight management.
How does Survodutide work?
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Combining appetite regulation with glucagon-driven energy expenditure, it is under study for obesity and for metabolic-associated fatty liver disease (MASH).
Cagrilintide vs Survodutide: how to choose
Choosing between Cagrilintide and Survodutide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. Cagrilintide is most associated with Appetite regulation and Weight management, while Survodutide leans toward Weight management and Liver health (MASH). Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. Cagrilintide is a long-acting amylin analog studied for appetite and weight, often with semaglutide; Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight and liver health. They're most researched for Appetite regulation, Weight management (Cagrilintide) and Weight management, Liver health (MASH) (Survodutide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
Cagrilintide: Clinical trials — investigational. Survodutide: Clinical trials — investigational.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.